PureTech Health/$PRTC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About PureTech Health
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Ticker
$PRTC
Sector
Primary listing
Employees
56
Headquarters
Website
PureTech Health Metrics
BasicAdvanced
$395M
83.88
$0.20
0.82
-
Price and volume
Market cap
$395M
Beta
0.82
52-week high
$21.90
52-week low
$13.30
Average daily volume
4K
Financial strength
Current ratio
8.487
Quick ratio
8.353
Long term debt to equity
38.476
Total debt to equity
44.326
Profitability
EBITDA (TTM)
-115.718
Gross margin (TTM)
-763.71%
Net profit margin (TTM)
792.96%
Operating margin (TTM)
-1,837.01%
Effective tax rate (TTM)
8.76%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-12.95%
Return on equity (TTM)
9.44%
Valuation
Price to earnings (TTM)
83.881
Price to revenue (TTM)
633.998
Price to book
0.78
Price to tangible book (TTM)
0.78
Price to free cash flow (TTM)
-40.394
Free cash flow yield (TTM)
-2.48%
Free cash flow per share (TTM)
-0.419
Growth
Revenue change (TTM)
1,265.60%
Earnings per share change (TTM)
-166.49%
3-year revenue growth (CAGR)
-29.94%
10-year revenue growth (CAGR)
-6.16%
3-year earnings per share growth (CAGR)
58.35%
10-year earnings per share growth (CAGR)
-3.53%
What the Analysts think about PureTech Health
Analyst ratings (Buy, Hold, Sell) for PureTech Health stock.
PureTech Health Financial Performance
Revenues and expenses
PureTech Health Earnings Performance
Company profitability
PureTech Health News
AllArticlesVideos
Puretech gains after FDA meeting post-Phase II trial
Proactive Investors·1 week ago
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Business Wire·1 week ago
PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PureTech Health stock?
PureTech Health (PRTC) has a market cap of $395M as of December 16, 2025.
What is the P/E ratio for PureTech Health stock?
The price to earnings (P/E) ratio for PureTech Health (PRTC) stock is 83.88 as of December 16, 2025.
Does PureTech Health stock pay dividends?
No, PureTech Health (PRTC) stock does not pay dividends to its shareholders as of December 16, 2025.
When is the next PureTech Health dividend payment date?
PureTech Health (PRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for PureTech Health?
PureTech Health (PRTC) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.